Coronavirus vaccine maker AstraZeneca has been given the all-clear by the UK competition watchdog to go ahead with its $39 billion (£28.2 billion) megadeal to buy U.S. drug company Alexion Pharmaceuticals.
The Competition and Markets Authority (CMA) said it had decided not to refer the acquisition for an in-depth investigation, paving the way for the deal to close on July 21.
